Nurix Therapeutics (NRIX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Nurix Therapeutics (NRIX) do?
Nurix Therapeutics Inc (NRIX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Discovers and develops small-molecule drugs that trigger cellular systems to destroy disease-causing proteins. Uses targeted protein degradation chemistry to destroy disease-causing proteins instead of merely blocking their. It is worth $1.49B on the market and sold $700.85M over the last year.
- Market cap
- $1.49B
- P/E ratio
- 5.9×
- Annual sales
- $700.85M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 08, 2026
NRIX’s flags, in plain English
Each flag is a number from Nurix Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.
Stupid Cash
Can pay this year's bills 8.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 7% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Fat Margins
Profit margin of 42%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Heavily Shorted
18.2% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about NRIX
How big is Nurix Therapeutics?
Nurix Therapeutics’ market cap is $1.49B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $700.85M: what customers paid the company over the last year, before any costs.
What is NRIX’s P/E ratio?
NRIX’s P/E ratio is 5.9×. Investors pay about 5.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with NRIX?
The company has no approved products and generates no commercial product sales to fund operating expenses. That is one risk on Nurix Therapeutics’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Nurix Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. NRIX’s filings on SEC.gov. The Margin Monkey is research, not advice.
